Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] clinical trials

Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema

This study is testing a new medicine, Dupilumab, for a skin condition called nummular eczema. Researchers want to see if it can improve symptoms like itching and skin patches. Dupilumab is already approved for a similar condition, atopic dermatitis.